This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.The Melanoma Staging Committee of the American Joint Committee on Cancer ( AJCC) was formed in 1998 and is comprised of ... The TNM categories for melanoma used in the 7th edition AJCC Staging Manual are outlined in Table 4.1 .
|Title||:||Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma|
|Author||:||Michael J. Murphy|
|Publisher||:||Springer Science & Business Media - 2011-12-02|